Skip to main content
Donate
Current Pipeline
FAST Logo Funded
ATF-ZF

UCD

University of California, Davis (UCD) is exploring the use of Artificial Transcription Factors/Zinc Fingers (ATF-ZF) as an approach to unsilence the paternal UBE3A gene as a treatment strategy for Angelman syndrome.

Pre-clinical

Discovery & Dev

Pre-clinical

Phase 1

Phase 2

Phase 3

To patients

  • progress mobile progress mobile progress mobile progress mobile progress mobile progress mobile

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.

Therapeutic Approach

A therapeutic approach that consists of using engineered proteins designed to regulate gene expression in a highly specific manner. They are constructed to bind to specific DNA sequences and can either activate or repress the expression of target genes. ATF-Zinc fingers are small proteins that use zinc ions to stabilize their structures giving them a finger-like appearance. ATF-ZFs can bind to the UBE3A-ATS and prevent the silencing of the paternal copy of the UBE3A gene.

Recent Updates

  • March 2023

    New UC Davis study reports behavioral rescue in a mouse model of Angelman syndrome

    Read More

Media

  • Progress Toward ATF and CRISPR Therapies for Angelman Syndrome

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.